Emilio Cortes-Sanchez

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

This paper demonstrates that multiparametric QPI can assess drug sensitivity in patient-derived breast cancer models, including cryopreserved samples, revealing cellular heterogeneity and resistance mechanisms.

This paper introduces ScreenDL, a deep learning model that predicts effective cancer therapies using tumor omic and drug screening data, outperforming existing methods in preclinical trials.

This study shows that dual FGFR/VEGFR inhibition causes regression of acral melanoma by targeting the tumor microenvironment rather than directly killing cancer cells.